New Biosimilar Approval Pathway Creates Device Opportunities
This article was originally published in The Gray Sheet
Executive Summary
A new abbreviated regulatory pathway established by Congress for the approval of off-patent recombinant protein therapeutics could open up U.S. market opportunities for injection device technology firms
You may also be interested in...
Intelliject Aims To Build Combination Product Biz On Ease-Of-Use Benefits
Human factors engineering has gained traction in the device industry in recent years, but Richmond-based Intelliject is a rare example of a firm trying to build a business around a focus on product usability
Hanmi And LG Chem Highlight Vaccine Prowess, Novel R&D At JPM
Hanmi showcases at JPM its contract production capabilities for COVID-19 vaccines as South Korea prepares to bring in candidates from several global developers, while LG Chem highlights progress across multiple pipeline projects.
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: